Inhaled steroid for wheezing in infants under 2
Part of Lungs & breathing clinical trials.
This trial tests whether a nebulized (inhaled mist) steroid medicine called fluticasone propionate helps reduce wheezing in infants under 2 years old. It aims to see if this treatment is safe and effective for babies who are hospitalized with wheezing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between birth and 24 months old.
- The wheezing and cough must have started within the last 3 days.
- Your child must be in the hospital with wheezing and crackles heard in the chest.
- Your child cannot have taken steroid medicine (like prednisone) for this current wheezing episode.
- Your child must not have certain serious health conditions (like severe heart defects, chronic lung disease, or tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of oral prednisolone (an anti-inflammatory steroid) helps young children under 2 who have wheezing triggered by a rhinovirus cold. It aims to see if steroid treatment can improve symptoms after an emergency visit.
This trial tests whether a medication can prevent wheezing after a baby's first chest infection, especially for those with risk factors. It may help reduce future breathing problems.
This study tests if giving oral steroids (medicine to reduce airway swelling) only when needed based on a child's own biology can help preschool children with wheezing. It aims to find the best treatment for each child, avoiding unnecessary medicine.
This trial studies whether an early steroid treatment can lower the chance that children will go on to develop asthma after their first severe “wheezing” episode caused by a rhinovirus (a common cold virus). If you qualify, the goal is to prevent future asthma rather than just treat the current episode.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
Hear when a new Acute Wheezing Disorders in Infants Aged 0 to 24 Months trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.